Results 111 to 120 of about 28,689 (318)

Alleviating the storm: ruxolitinib in HLH [PDF]

Blood, 2016
In this issue of Blood, Das and colleagues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murine models of hemophagocytic lymphohistiocytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).
openaire   +2 more sources

Recent Synthetic Advances in C–H/N–H Functionalization of 1H‐Pyrazoles: Diverse Strategies Across Variously Substituted Scaffolds

The Chemical Record, EarlyView.
Systematic overview of pyrazole functionalization reactions from C‐5 to N−H. It covers different strategies, from traditional cross‐coupling of prefunctionalized pyrazoles to more efficient direct functionalizations. This review briefly and systematically overviews C–H and N–H functionalization reactions of pyrazoles, aimed at creating new CC and C ...
Karolina Dzedulionytė Müldür, Asta Žukauskaitė, Algirdas Šačkus, Eglė Arbačiauskienė   +3 more
wiley   +1 more source

Ruxolitinib and effect mechanisms

Istanbul Bilim University Florence Nightingale Journal of Medicine, 2016
Ruxolitinib JAK1 ve JAK2 tirozin kinazlarinin inhibitorudur. Jakafi adiyla piyasaya surulen ruxolitinib, miyelofibroz tedavisinde onaylanan ilk kimyasalajan olarak 2011 yilindan beri kullanilmaktadir. Miyeloproliferatif neoplazmlar (MPN) Philadelphia kromozom (Ph) pozitif ve negatif hastaliklari icerir.2001 yilinda imatinib tirozin kinazinin ...
Bakiye Goker Bagca, Cigir Biray Avci
openaire   +2 more sources

Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Over 5000 patients are newly diagnosed with Alopecia areata (AA) in Australia each year. AA severity varies from a single small patch to complete loss of scalp hair, body hair including eyelashes and eyebrows. Approximately 40% of affected individuals experience only a single patch and achieve spontaneous, complete and durable remission within
Daniella Kushnir‐Grinbaum, Laita Bokhari, John Frewen, Anthony Moussa, Daranporn Triwongwaranat, Ragini Ghiya, Flavia Rodrigues Dias, Shin Shen Yong, Bevin Bhoyrul, Zeyad Dabbagh, Ahmed Kazmi, Adam Daunton, Jane Li, Leona Yip, Vivian Lai, Katherine York, William Cranwell, Dmitri Wall, Samantha Eisman, Rodney Sinclair   +19 more
wiley   +1 more source

BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. [PDF]

, 2013
Small molecule inhibition of the BET family of proteins, which bind acetylated lysines within histones, has been shown to have a marked therapeutic benefit in pre-clinical models of mixed lineage leukemia (MLL) fusion protein-driven leukemias.
Bannister, AJ, Barbieri, I, Calero-Nieto, FJ, Cannizzaro, E, Dawson, MA, Godfrey, A, Gottgens, B, Green, AR, Huntly, B, Kouzarides, T, Li, J, Nangalia, J, Prinjha, RK, Rioja, I, Robson, S, Wiese, M, Wyspiańska, BS   +16 more
core   +1 more source

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

Primary myelofibrosis with increased haemoglobin concentration at presentation

British Journal of Haematology, EarlyView.
Subjects with primary myelofibrosis and elevated haemoglobin levels at diagnosis tend to have longer survival rates (OS) and blast transformation‐free survival (BTFS) than those with normal or reduced haemoglobin levels. Summary One hundred of 963 consecutive registrants with primary myelofibrosis (PMF) in the Pavia‐CSM database had haemoglobin ...
Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Carlotta Abbà, Adriana Carolei, Margherita Massa, Annalisa De Silvestri, Robert Peter Gale, Vittorio Rosti   +8 more
wiley   +1 more source

Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives

Dermatology and Therapy
Introduction The 2021 US approval of ruxolitinib cream for treatment of atopic dermatitis (AD) in patients aged ≥ 12 years was based on the results of two pivotal phase 3 studies.
Lawrence F. Eichenfield, Jinan Liu, Simran Marwaha, James Piercy, Daniel Sturm, Peter Anderson   +5 more
doaj   +1 more source

Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial

Journal of Dermatological Treatment
Purpose Ruxolitinib cream was evaluated in patients with facial/neck atopic dermatitis (AD) in a decentralized, double-blind, randomized clinical trial (NCT05127421).Materials and methods Patients aged 12–70 years with AD (Investigator’s Global ...
Zelma C. Chiesa Fuxench, Zhihong Lai, YuTzu Kuo, Haq Nawaz, Jonathan Cotliar   +4 more
doaj   +1 more source

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib [PDF]

, 2012
John Mascarenhas, Tariq I. Mughal, Srđan Verstovšek   +2 more
openalex   +1 more source